XML 100 R23.htm IDEA: XBRL DOCUMENT
v3.26.1

Interests in equity-accounted investees | 12 Months Ended
--- | ---
Dec. 31, 2025
Disclosure of associates [abstract] |
Interests in equity-accounted investees | Interests in equity-accounted investees
| 2025 |  | 2024
Interests in associates | $ | 66,109 |  |  | $ | 68,223 |
Particulars of equity-accounted investees of the Group are as follows:
Name of an equity-accounted investee | Place of incorporation/ operation |  | Particular of issued and paid-up capital |  | Proportion of nominal value of issue capital held by the Company |  | Principal activity
|  |  |  |  | 2025 |  | 2024 |  |
|  |  |  |  | Directly |  | Indirectly |  | Directly |  | Indirectly |  |
|  |  |  |  | % |  | % |  | % |  | % |  |
Insighta | Cayman Islands |  | 2,000,000 ordinary shares |  | 35 |  |  | — |  |  | 35 |  |  | — |  |  | Multi-cancer genetic testing services
CERBACT Asia Holdings Pte. Ltd. (“CERBACT”) | Singapore |  | 100 ordinary shares |  | — |  |  | — |  |  | — |  |  | 26.04 |  |  | Investment holdings
Insighta Insighta represents an associate in which the Group has a 35 percent ownership interest and joint control under a transactional agreement. Insighta is not publicly listed. On July 20, 2023, the Group acquired 50% shareholdings of an equity-accounted investee, Insighta. This involved a total consideration of $80,000 contribution in cash to the joint venture and an issuance of 1,481,481 Class A ordinary shares. The fair value of the ordinary shares issued was based on the listed share price of the Company at July 20, 2023 of $0.83 per share (equivalent to $12.51 per share after reverse stock split). The joint venture partner entered into a license agreement with the joint venture that will be automatically terminated upon the occurrence of certain events, including the cessation of business and liquidation of the joint venture. On October 14, 2024, the Group’s shareholding in Insighta was reduced to 35% following the disposal of 15% equity interest in Insighta to a third party with a cash consideration of $30,000. As such, investment in Insighta was reclassified as interests in associate in 2024. Subsequent to the reporting period, the Group further disposed of its interest in Insighta. Details are set out in note 39. The following table summarizes the financial information of Insighta, for the years ended December 31, 2025 and 2024, as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The table also reconciles the summarized financial information to the carrying amount of the Group's interest in Insighta recognized in the consolidated financial statements.
| 2025 |  | 2024
Non-current assets | $ | 122,253 |  |  | $ | 127,005 |
Current assets (including cash and cash equivalents $80,153 (2024: $81,005)) | 80,568 |  |  | 81,388 |
Non-current liabilities | (13,513) |  |  | (14,417) |
Other payables, accruals and contract liabilities | (316) |  |  | (238) |
Amount due to a related company | (110) |  |  | (1,179) |
Equity | $ | 188,882 |  |  | $ | 192,559 |
Proportion of the Group’s interest in the associate | 35 | % |  | 35 | %
Carrying amount of the Group’s interest in the associate | $ | 66,109 |  |  | $ | 67,396 |
| 2025 |  | 2024
Other income | $ | 86 |  |  | $ | 31 |
Other gains or losses | 266 |  |  | — |
Interest income | 3,467 |  |  | 4,775 |
Depreciation and amortization | (5,082) |  |  | (5,677) |
Other expenses | (3,174) |  |  | (4,459) |
Income tax expense | 836 |  |  | 841 |
Loss for the year | $ | (3,601) |  |  | $ | (4,489) |
Item that may be reclassified subsequently to profit or loss: |  |  |
Exchange differences on translation of foreign operations | (75) |  |  | 597 |
Total comprehensive expense for the year | $ | (3,676) |  |  | $ | (3,892) |
Group's share of loss and total comprehensive expense | $ | (1,286) |  |  | $ | (1,707) |
Dividends received by the Group | $ | — |  |  | $ | — |
Change in the group’s ownership interest in Insighta In 2024, the Group disposed of 15% in Insighta to a third party for proceeds of $30,000. The Group has accounted for the remaining 35% as interests in associates. This transaction has resulted in the recognition of a gain in profit or loss, calculated as follows:
| 2024
Proceeds of disposal | $ | 30,000 |
Fair value of interest retained - 35% | 67,954 |
Carrying amount of interest on the date of disposal | (96,710) |
Gain recognized | $ | 1,244 |
CERBACT CERBACT represents an associate and was incorporated on July 12, 2021 as a limited liability company in Singapore. CERBACT is not individually material to the Group and is not publicly listed. The Group’s interest in CERBACT was held indirectly through a subsidiary. Following the disposal of that subsidiary on October 1, 2025, the Group ceased to have an indirect interest in CERBACT, and therefore, the Group’s share of (loss)/profit and comprehensive (expense)/income are disclosed in note 10. Aggregate information of associates that are not individually material:
| 2025 |  | 2024
Carrying amount of interest in CERBACT | $ | — |  |  | $ | 827 |
Group's share of (loss)/profit and total comprehensive (expense)/income | (868) |  |  | 231 |

X
- Definition The entire disclosure for interests in other entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 1 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_1&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration